Home CONTACT Neoplasma 2010 Neoplasma Vol.57, No.5, p.401-405, 2010

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.57, No.5, p.401-405, 2010

Title: PARP-1 inhibitors: a novel genetically specific agents for cancer therapy
Author: L. Cipak, S. Jantova

Abstract: The nuclear poly(ADP-ribose) polymerase-1 (PARP-1) represents an important novel target in cancer therapy. The enzyme is essential for single strand DNA breaks repair via base excision repair pathway. Inhibition of PARP-1 exerts „synthetic lethality“ effect towards the tumors with defects in DNA repair by homologous recombination, specifically the tumors with mutations in the breast cancer associated BRCA1 and BRCA2 genes. Recent clinical data confirmed the early in vitro studies and suggest that PARP-1 inhibitors could be used not only as chemosensitizers but as well as single agents to selective kill tumors with defective DNA repair by homologous recombination. Such concept of „synthetic lethality“ for tumors which have lost one DNA repair pathway by targeting a second DNA repair pathway, represents groundbreaking therapeutic strategy. The review highlights our current knowledge and ongoing clinical development/trials of PARP-1 inhibitors.

Keywords: PARP-1 inhibitor, BRCA1, BRCA2, DNA repair, synthetic lethality
Year: 2010, Volume: 57, Issue: 5 Page From: 401, Page To: 405
doi:10.4149/neo_2010_05_401
Price: 12.00 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.